Article Sidebar

Submitted
Apr 19, 2021
Published
Apr 19, 2021
Download
PDF
Statistic
Read Counter : 47 Download : 20

Main Article Content

Abstract

Rheumatoid arthritis is a chronic systemic inflammatory disorder affecting  joints leading to limited range of motion affecting daily activities. Various drug therapies were used to preserve range of motion; joint function and to prevent systemic complications.


But due to serious adverse effects of the drugs and limited improvement a 'Novel drug free implant' is introduced to improve quality of life and reduce adverse effects of the drugs. This drug free implant works through electric stimulation of peripheral nerve as a treatment for immune disease.


This article is  a review on assessing various drugs used to treat Rheumatoid arthritis comparing it's efficacy and advantages of 'Drug free implant' over other drug therapy. It is assessment of various anti-rheumatic drugs related adverse effects and safety profile.

Keywords

Rheumatoid arthritis Drug Free Implant Triple therapy Dual Therapy Tofacitinib PRT-318

Article Details

How to Cite
Fatma Ali, Unnisa Begum Faiz, Nikhat Sara, & Fatima Sara. (2021). Review of various treatment strategy for rheumatoid arthritis. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(1), 113-118. https://doi.org/10.61096/ijrpp.v4.iss1.2015.113-118
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] Iain B. McInnes and Georg Schett "The Pathogenesis of Rheumatoid Arthritis" N Engl J Med 2011; 365:2205-2219.
  2. [2] Kumar P1, Banik S. "Pharmacotherapy options in rheumatoid arthritis." Clin Med Insights Arthritis Musculoskelet Disord. 8;6:35-43
  3. [3] Ronald F. van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, "Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis".
  4. [4] James R. O’Dell, Ted R. Mikuls,. Thomas H. Taylor, Vandana Ahluwalia Warren, J.D., "Therapies for Active Rheumatoid Arthritis after Methotrexate Failure" N engl j med 369;4.
  5. [5] 5. Takeda K1, Kaisho T, Akira S. Toll-like receptors." Annu Rev Immunol.
  6. [6] Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al "Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer". J. Clin. Oncol. 23 (25): 5950–9.
  7. [7] Michael E. Weinblatt,, Arthur Kavanaugh Mark C. Genovese "An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis" N engl j med 363;14
  8. [8] Article by Kevin J trace
  9. [9] Research article by Susan young rojhan on August 22, 2013
  10. [10] Chris Vaillancourt" Implantable Pulse Generators ‘Stimulate’ Medical Device'
  11. [11] James R.O`Dell ."Therapies for Active Rheumatoid Arthritis after Methotrexate Failure". N Engl J Med 2013;369:307-18.
  12. [12] Michael E. Weinblatt,. "An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis". N Engl J Med 2010;363:1303-12.
  13. [13] Ronald F. van vollenhoven, "Tofacitinib or adalimumab versus placebo in Rheumatoid Arthritis", N Engl J Med 2012;367:508-16
  14. [14] Susan Young Rojahn. "A nerve-stimulating electrical implant could give people a drug-free alternative to current treatments." August 22, 2013.
  15. [15] Ulf Andersson, "A New Approach to Rheumatoid Arthritis: Treating Inflammation with Computerized Nerve Stimulation". . August 22, 2013.